摘要
目的探讨替吉奥治疗中晚期肺癌的近期疗效和安全性。方法选择2010年1月至2012年4月收治的中晚期肺癌患者83例,按照随机数字表法分为观察组和对照组,对照组患者(40例)采用多西他赛联合顺铂治疗,观察组患者(43例)采用多西他赛联合替吉奥治疗,观察两组患者的治疗情况。结果观察组患者的有效率为81.4%,明显高于对照组的57.5%,差异有统计学意义(P<0.05)。治疗后两组患者的血清中肿瘤标志物癌胚抗原(CEA)、癌抗原125(CA125)、神经元特异性烯醇化酶(NSE)水平均明显改善,且观察组患者改善更为明显,组间差异均有统计学意义(P<0.05)。观察组患者不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论替吉奥治疗中晚期肺癌近期疗效满意,安全性可靠,能够明显改善患者血清肿瘤标志物CEA、CA125和NSE的水平。
Objective To observe the efficacy and safety of tegafur chemotherapy in the treatment of middle-advanced lung cancer. Methods From January 2010 to April 2012 in our hospital, 83 cases of middle-advanced lung cancer were selected and randomly divided into two groups according to random num- ber table, the control group （40 cases） treated with docetaxel and cisplatin, the observation group （43 ca- ses） treated with docetaxel and tegafur, the treatment data of two groups were compared and analyzed. Results The effective rate of observation group was 81.4%, significantly higher than 57. 5% of the control group, the difference was statistically significant between two groups （P 〈 0. 05） ; after treatment, the ser- um tumor markers carcinoembryonic antigen （CEA）, cancer antigen 125 （CA125）, neuron-specific enolase （NSE） level of patients in two groups were significantly improved, and the observation group improved more obvious, the differences were statistically significant between two groups （ P 〈 0.05 ） ; the side effects oc- curred in the observation group was significantly less than that of the control group, the difference was statis- tically significant between two groups （P 〈 0.05）. Conclusions Tegafur chemotherapy in the treatment of middle-advanced lung cancer has satisfactory clinical efficacy and reliable security, can significantly improve patients＇ serum markers CEA, CA125 and NSE level, it is worthy referred in clinic.
出处
《中国肿瘤临床与康复》
2013年第4期359-361,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
肺肿瘤
药物疗法
替吉奥
多西他赛
顺铂
Lung neoplasms
Drug therapy
Tegafur
Docetaxel
Cisplatin
